Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure

Johanna K. Freundt,
Gerrit Frommeyer,
Tilmann Spieker,
Fabian Wötzel,
Jochen Schulze Grotthoff,
Jörg Stypmann,
Georg Hempel,
Michael Schäfers,
Andreas H. Jacobs,
Lars Eckardt and
Philipp S. LangeEmail author View ORCID ID profile

BMC Pharmacology and Toxicology201920:16

https://doi.org/10.1186/s40360-019-0294-x

Received: 12 December 2017
Accepted: 26 February 2019
Published: 6 March 2019

Open Peer Review reports

Abstract

Background

The development of heart failure is accompanied by complex changes in cardiac electrophysiology and functional properties of cardiomyocytes and fibroblasts. Histone deacetylase (HDAC) inhibitors hold great promise for the pharmaceutical therapy of several malignant diseases. Here, we describe novel effects of the class I HDAC inhibitor Entinostat on electrical and structural remodeling in an in vivo model of pacing induced heart failure.

Methods

Rabbits were implanted a pacemaker system, subjected to rapid ventricular pacing and treated with Entinostat or placebo, respectively. Following stimulation, rabbit hearts were explanted and subsequently subjected to electrophysiological studies and further immunohistological analyses of left ventricles.

Results

In vivo, rapid ventricular stimulation caused a significant prolongation of monophasic action potential duration compared to sham hearts (from 173 ± 26 ms to 250 ± 41 ms; cycle length 900 ms; p < 0.05) and an increased incidence of Early afterdepolarisations (+ 150%), while treatment with Entinostat in failing hearts could partially prevent this effect (from 250 ± 41 ms to 170 ± 53 ms, p < 0.05; reduction in EAD by 50%). Entinostat treatment partially restored KCNH2 and Cav1.3 gene expressions in failing hearts, and inhibited the development of cardiac fibrosis in vivo.

Conclusion

In a rabbit model of heart failure, Entinostat diminishes heart failure related prolongation of repolarization and partially restores KCNH2 and Cav1.3 expression. In addition, Entinostat exerts antifibrotic properties both in vitro and in vivo. Thus, Entinostat might be an interesting candidate for the pharmaceutical therapy of heart failure directed against structural and electrical remodeling.